IP Library Granted Patent US 9,598,412
Granted Patent B2
US 9,598,412 · App. 14/513,929 · Granted Mar 21, 2017

Spiroindoline compounds for use as anthelminthics

Inventors: Jürgen Lutz (Schwabenheim, DE); Sandra Koch (Schwabenheim, DE); Manfred Uphoff (Schwabenheim, DE); Anja Regina Heckeroth (Schwabenheim, DE); Britta von Oepen (Schwabenheim, DE); Ulrich Sondern (Schwabenheim, DE); Christophe Pierre Alain Chassaing (Schwabenheim, DE)
Assignee: Intervet Inc.
C07D471/10A61K31/438A61K31/444A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,598,412
App. No.
14/513,929
Granted
Mar 21, 2017
Kind
B2
Abstract

This invention relates to spiroindoline compounds for the treatment of helminth infections and the treatment of parasitosis, such as caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. Moreover this invention relates to pharmaceutical compositions and kits comprising the compounds.

Claims (9)

1. A method of treating a parasitic infection in an animal comprising administering to the animal a pharmaceutical composition comprising a compound selected from the group consisting of

and pharmaceutically acceptable solvates, N-oxides and salts thereof.

2. The method of claim 1 , wherein the pharmaceutical composition, further comprises one or more pharmaceutically acceptable excipients, and/or one or more pharmaceutically acceptable active ingredients which differ in structure from the compounds of claim 1 .

3. The method of claim 1 , wherein the helminth infection is a nematode infection.

4. The method as claimed in claim 1 , wherein one or more of the parasites are resistant to one or more antiparasitic compounds.

5. The method of claim 1 , wherein the animal is a non-human mammal.

6. The method of claim 1 , wherein the pharmaceutical composition is administered orally.

7. The method of claim 1 , wherein the pharmaceutical composition is administered parenterally.

8. The method of claim 1 , wherein the compound selected from the group consisting of

Assignments (1)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
Priority Claims (1)
EP 10152817 · Feb 5, 2010 · regional
Continuity (3)
Division 13574900
Provisional Application 61302312 · Feb 8, 2010
Related Publication 20150057302A1 · Feb 26, 2015